China's novel coronavirus infection (COVID-19) has a great impact on the life of HIV infected people in China, according to a survey by UNAIDS.

Source: STD / AIDS prevention and control center of China Center for Disease Control and Prevention

China's novel coronavirus infection (COVID-19) has a great impact on the life of HIV infected people in China, according to a survey by UNAIDS.

In the survey, nearly one-third (32.6%) of people living with HIV said they faced the risk of drug interruption in the near future due to blockade and traffic control in some areas, while nearly half (48.6%) of these people said they did not know where to get antiviral drugs next. For this reason China novel coronavirus is working with the Chinese government and community to ensure that the HIV virus infection is not affected by the new coronavirus.

The center for STD and AIDS prevention and control (NCAIDS) of the China Center for Disease Control and Prevention (CDC) has taken active measures, including sending a notice to the AIDS prevention and control institutions all over the country to ensure that people living with HIV can get drugs no matter where they are. At the same time, it has also published the contact information of anti-virus treatment points in all regions. In addition, UNAIDS China office and community partners such as baihualin National Alliance are gathering and helping to collect the list of HIV infected people who are about to face drug shortages in the next 10-14 days. Novel coronavirus is also being donated by hospitals, civil society organizations and other organizations providing services to HIV infected people.

"People living with HIV must continue to have access to HIV drugs to continue their lives," said Winnie byanyima, executive director of UNAIDS. "I appreciate the efforts of the center for HIV prevention and control to ensure access to drugs for people affected by the closure of the city, to ensure that all those in need of treatment, wherever they are, have access to drugs. "

China has hitherto unknown novel coronavirus control measures to novel coronavirus. As a result of the closure measures, people living with HIV cannot return to their original places of residence and treatment, and thus cannot obtain drugs from the original medical units.

Novel coronavirus infection was the most common information of the HIV infected respondents (82%), although most respondents were aware of the information they needed to assess their personal risk and take measures to prevent new coronavirus infection. However, nearly 90% of respondents still wanted more information on how specific measures should be taken for HIV infected persons. Like other people, many people with HIV (more than 60%) say they don't have enough personal protective equipment, such as masks, disinfectants, medical alcohol or gloves. Nearly 1/3 said novel coronavirus outbreak was a period of anxiety and psychological support.

Novel coronavirus novel coronavirus is novel coronavirus, and it is more dangerous for HIV infected persons to infect the new coronavirus and to infect new coronaviruses. During novel coronavirus outbreak, there are still many unknown aspects. We need to fill in these knowledge gaps quickly. "

The online survey was jointly sponsored by UNAIDS and birch forest national HIV alliance. UNAIDS mobilized the community to participate in the survey actively to make more infected people participate in the response. From February 5 to 10, 2020, more than 1000 HIV carriers have received their responses. Next, UNAIDS will cooperate with the school of medicine of Sun Yat sen University to conduct a more in-depth investigation. In addition to focusing on community needs, it will also explore the problems that directly affect AIDS services in the health care system. (source: official account of UNAIDS)

Over the years, through the unremitting efforts of experts from various countries, anti HIV drugs have also been developed to give hope to AIDS patients, so the attitude of patients has gradually changed from negative to positive treatment. At present, there are more than 30 kinds of anti HIV drugs on the market in the world. The categories include nucleoside reverse transcriptase inhibitors, non nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, integrase inhibitors and CCR5 receptor inhibitors. These drugs can effectively inhibit and block the incidence rate of AIDS, but because of the specificity of AIDS, and after suppression and blocking, there is a high probability of recurrence. So the drug control rate of HIV is still very low.

With the emergence of polypeptide drugs in recent years, experts have turned their attention to polypeptide drugs because of their wide indications and high safety and significant curative effect. After a long time of efforts, they finally developed a polypeptide drug for HIV control combined with anti retrovirus and blocking - enfuweitai for injection,

Because AIDS is different from general diseases, even the control rate of anti HIV drugs is not high, and even some patients will have relapse after blocking treatment, and the role of injection of enfweptide is to use it in combination with other antiretroviral drugs to treat HIV-1 infected patients who still have HIV-1 replication after other antiretroviral drugs. After clinical use, the effect is very significant, this product has also been widely used in HIV blocking and control treatment.

With the success of the research and development of enfwetide for injection, this terrible devil has gradually become controllable. It can be said that China has taken another important step in anti HIV.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.